{
}
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Intra-Cellular Therapies has reached a settlement with Sandoz regarding patent litigation for its product Caplyta, marking Sandoz as the first of seven ANDA filers to finalize a deal. RBC Capital views the favorable terms as a positive sign for Caplyta's revenue stability and maintains an Outperform rating with a $108 price target on the shares.
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) rose following the resolution of a patent dispute with Sandoz (OTCQX:SDZNY) regarding its antipsychotic drug, Caplyta (lumateperone). The agreement comes as Sandoz submitted an abbreviated new drug application, signaling progress in the generic market.
Intra-Cellular Therapies has settled patent litigation with Sandoz regarding its product CAPLYTA® (lumateperone). The agreement allows Sandoz to market a generic version starting July 1, 2040, or earlier under specific conditions, following Sandoz's submission of an Abbreviated New Drug Application. Intra-Cellular will submit the settlement to the U.S. Federal Trade Commission and the U.S. Department of Justice, while other related litigation remains ongoing.
The Congestive Heart Failure market is poised for significant growth, driven by an increase in prevalence and the introduction of innovative therapies like finerenone, tirzepatide, and semaglutide. Key players such as Novartis, Eli Lilly, and Bayer are advancing their drug candidates through clinical development, while off-label therapies and generics continue to dominate the current market landscape. The FDA's recent approvals and label expansions are expected to further enhance treatment options and accessibility for patients.
Intra-Cellular Therapies, Inc.
Companies
| Symbol | ITCI |
| Name | Intra-Cellular Therapies, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | NY |
| City | New York |
| Zipcode | 10016 |
| Website | http://www.intracellulartherapies.com |
16:40 11.01.2025
17:05 10.01.2025
12:51 10.01.2025
United States Dollar
Mesoblast Ltd
Eli Lilly and Co
Boehringer Ingelheim KG
Bayer AG
Merck & Co., Inc.
Bristol-Myers Squibb Co
Intra-Cellular Therapies, Inc.
BioCardia, Inc.
Novo Nordisk A/S
scPharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc.
Cytokinetics, Incorporated
Novartis AG
Tenax Therapeutics, Inc.
AstraZeneca PLC
Amgen Inc.
Otsuka Pharmaceutical Co. Ltd.
FRA
DEU
ITA
JPN
GBR
USA
Show more
15:50 07.01.2025
Trending
Subcategory:
Cryptocurrency Markets
Cryptocurrency Trends
Stock Market Updates
Market Sentiment Analysis
Decentralized Finance (DeFi) Innovations
Central Bank Actions
Market Analysis and Predictions
Tokenomics and Crypto Economics
Inflation Rates & CPI Data
Hedge Funds & Private Equity
Cryptocurrency & Blockchain Regulations
Banking Regulations
Employment Reports
Cryptocurrency Regulations
Anti-Money Laundering (AML) Regulations
ESG & Sustainable Finance Regulations
Corporate Responsibility & ESG
Anti-Money Laundering (AML) & Know Your Customer
Blockchain Technology Adoption
Banking & Investment Regulations
Countries:
Companies:
Currencies:
People:
Apple Inc.
Ethereum USD
Solana USD
Ripple USD USD
Bitcoin USD
Coinbase Global, Inc.
Santiment Network Token USD
Bitwise Bitcoin ETF
NVIDIA Corporation
Ripples USD
JPMorgan Chase & Co.
BlackRock, Inc.
MicroStrategy Inc
Taiwan Semiconductor Manufacturing Co Ltd
Chainlink USD
Grayscale Bitcoin Trust ETF
Heritage Distilling Holding Company, Inc.
Robinhood Markets, Inc.
MARATHON DIGITAL
End Federal Reserve USD
United States Dollar
Armenian Dram
Euro
Vietnamese Đồng
British Pound Sterling
Canadian Dollar
New Zealand Dollar
Australian Dollar
Philippine Peso
Malagasy Ariary
Japanese Yen
Singapore Dollar
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.